Trial Profile
A Phase I, Single Centre, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD2423 Solution After Administration of Multiple Ascending Doses for 12 Days in Young and Elderly Healthy Japanese Volunteers.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 23 Apr 2011
Price :
$35
*
At a glance
- Drugs AZD 2423 (Primary)
- Indications Chronic obstructive pulmonary disease; Neuropathic pain
- Focus Adverse reactions
- 08 Dec 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 15 Nov 2010 New trial record